# Reforgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reforgene

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.reforgene.com
- Total disclosed funding: $30M
- Latest round: Series A (Sep 17, 2021)
- Investors on record: 7

## About

Established in 2019 and based in Guangzhou, China, Reforgene operates as a gene editing therapy company that focuses on the production and sales of gene and cell therapy drugs. It was recognized as the National High-tech Enterprise. The company has nearly 7000 square meters of research and development sites and pilots. Junbin Liang, the company's CEO, graduated from Sun Yat-sen University and used to work at Shenzhen BGI and the Guangdong Institute of Microbiology, Chinese Academy of Sciences. In December 2024, Reforgene closed a venture funding.

The company's main business is to develop gene and cell therapy drugs. Combining gene editing, RNA technology and bioinformatics, it develops pipeline drugs for the treatment of thalassemia, malignant tumors and other diseases. The company also provides services such as gene editing tool innovation, drug strategy discovery, new animal model construction, and multi-level efficacy and safety evaluation.

The company generates revenue by providing gene and cell therapy drugs and related services.

The company will use the venture funding to promote clinical trials of gene-editing drugs, subsequent R&D pipeline expansion, and core technology innovation.

## Funding rounds

- Series A, Sep 17, 2021, $15M — China Everbright, YuanBio Venture, China Merchants Securities, Innovation Works, BioTrack Capital
- Series A, Nov 2, 2020, $15M — Legend Star, Alwin Capital
- Angel, Jan 18, 2019 — Legend Star

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel, Series A
- Alwin Capital — Series A
- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- China Merchants Securities — Series A
- Innovation Works (https://capitalatlas.ai/funds/innovation-works) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A